

# Meta-Analysis of the Association Between Asthma and the Risk of Stroke

Zheng-Hua Fang<sup>1\*†</sup>, Zhi-Fei Li<sup>2†</sup>, Zhuo-Yu An<sup>3†</sup>, Si-Cheng Huang<sup>2</sup>, Meng-Di Hao<sup>2</sup> and Wei-Xing Zhang<sup>4</sup>

<sup>1</sup> The First People's Hospital of Jiande, Hangzhou, China, <sup>2</sup> Aerospace Center Hospital, Beijing, China, <sup>3</sup> Peking University People's Hospital, Beijing, China, <sup>4</sup> Department of Respiratory Medicine, The First People's Hospital of Jiande, Hangzhou, China

**Introduction:** Asthma and stroke share many risk factors. Previous meta-analysis has indicated that asthma is associated with an increased risk of stroke. However, this study were limited by the small number of articles included and the lack of subgroup analyses of different stroke types and different populations. This meta-analysis aimed to synthesize evidence systematically to investigate the impact of asthma on stroke.

#### **OPEN ACCESS**

#### Edited by:

Sy Duong-Quy, Lam Dong Medical College, Vietnam

#### Reviewed by:

Vinh Nguyen, University of Medicine and Pharmacy at Ho Chi Minh City, Vietnam Lam Hoang Thi, Hanoi Medical University, Vietnam

> \*Correspondence: Zheng-Hua Fang fzh2025@163.com

<sup>†</sup>These authors have contributed equally to this work and share first authorship

#### Specialty section:

This article was submitted to Neuroepidemiology, a section of the journal Frontiers in Neurology

Received: 08 April 2022 Accepted: 17 May 2022 Published: 24 June 2022

#### Citation:

Fang Z-H, Li Z-F, An Z-Y, Huang S-C, Hao M-D and Zhang W-X (2022) Meta-Analysis of the Association Between Asthma and the Risk of Stroke. Front. Neurol. 13:900438. doi: 10.3389/fneur.2022.900438 **Methods:** We searched Medline (*via* PubMed), Web of Science and EMBASE databases and manually identified eligible studies (inception dates to December 25, 2021) that analyzed the association between asthma and stroke. We conducted quality assessment to evaluate the risk of bias of studies and sensitivity analyses to test the robustness of results.

**Results:** We included 8 cohort studies and 10 cross-sectional studies comprised 3,011,016 participants. We found patients with asthma had a higher risk of stroke than patients without asthma [relative risk (RR): 1.34, 95% confidence interval (CI): 1.21–1.47]. Moreover, asthma significantly increased the risk of ischemic stroke (RR: 1.25, 95% CI: 1.06–1.47) without increasing the risk of hemorrhagic stroke (RR: 1.08, 95% CI: 0.87–1.34). Asthma increased the risk of stroke in both men (RR: 1.20, 95% CI: 1.10–1.32) and women (RR: 1.29, 95% CI: 1.12–1.48) with no significant difference between the sexes. We also found that patients with inactive asthma, child-onset asthma, or no smoking history did not have an increased risk of stroke.

**Conclusions:** These results supported the finding that asthma could significantly increase the risk of stroke, but this impact was not consistent in different populations.

**Systematic Review Registration:** https://www.crd.york.ac.uk/PROSPERO/display\_r ecord.php?RecordID=290745, identifier: CRD42021290745.

Keywords: asthma, the risk of stroke, morbidity, meta-analysis, different population groups

# INTRODUCTION

Asthma is a common chronic inflammatory disease. Globally, it is estimated that 334 million people have asthma, including children and adults (1). The incidence of asthma continues to increase, particularly in places with a western lifestyle (2), which aggravates the health and financial burden of society.

1

Patients with asthma have reduced lung function and a high risk of comorbidities. Essentially, asthma is due to chronic airway inflammation, and the main features are airway hyper-reactivity and reversible airway limitation. However, chronic asthmatic inflammation is not limited to the airway, but affects the whole body (3, 4). Consequently, asthma is a risk factor for stroke (5). In addition, asthma and stroke share other risk factors, including smoking and obesity (6, 7).

Stroke is responsible for over 5.5 million deaths annually, and it is estimated that 166 million healthy-life years are lost due to stroke (8). The question of whether asthma increases the risk of stroke is currently unresolved, and it has become a hot topic at the intersection of respiratory medicine and neurology (9, 10).

Considering the growing incidence of asthma and the high disability rate and mortality associated with stroke, there is an urgent need to determine how asthma affects the risk of stroke. Moreover, knowledge about the degree of stroke risk induced by asthma in different populations will assist in developing population-wide interventions. In addition, this knowledge could inform the clinical management of patients with asthma that have high stroke risk.

A previous meta-analysis of 5 cohort studies noted that asthma was associated with an increased risk of stroke (11). However, due to insufficient data in the studies included, that review failed to analyze the stroke risk in different populations with asthma. To avoid these limitations and provide reliable evidence, we conducted a meta-analysis that included cohort studies and cross-sectional studies to investigate the impact of asthma on stroke.

## MATERIALS AND METHODS

This meta-analysis was conducted according the MOOSE (Meta-Analysis of Observational Studies in Epidemiology) and PRISMA (Preferred Reporting Items for Systematic Reviews and Meta-Analyses) checklist (**Supplementary Table 1**), to ensure quality (12). This meta-analysis was previously registered on the International Prospective Registry of Systematic Reviews (PROSPERO Identifier: CRD 42021290745).

### **Literature Search**

We searched electronic databases up to December 25, 2021 (PubMed, EMBASE). The detailed search terms are provided in **Supplementary Table 2**. In addition, to ensure the adequacy of the included studies, we conducted a manual search.

# **Selection Criteria and Outcomes of Interest**

We included observational cohort studies with both prospective and retrospective designs. The inclusion criteria were: both asthma and control groups had to be included; the total number of subjects had to be > 1,000, to reduce bias; outcome measures had to include an analysis of the association between asthma and stroke; and the data had to include hazard ratios (HRs), relative risks (RRs), odds ratios (ORs), or the number of stroke events in the asthma and control groups.

# **Data Abstraction**

The titles and abstracts of eligible studies were analyzed independently by two independent investigators (Z-FL and Z-YA). Disagreements were settled by discussing with a third author (Z-HL) to reach a consensus. Then, the reviewers independently assessed the full text of all studies for inclusion, based on the criteria related to population selection, study design, and outcome. The investigators also attempted to contact the corresponding author for information on missing data.

# Assessment of the Risk of Bias

The risk of study bias and quality were assessed with the Newcastle-Ottawa Scale (NOS) for cohort studies. NOS scores below 6 indicated low quality, NOS scores of 6 or 7 indicated medium quality, and NOS scores above 7 indicated high quality. Two authors (S-CH and M-DH) independently completed the quality assessments. In cases of disagreement, a third investigator (Z-FL facilitated the discussion and made the final decision).

# Data Analysis

We pooled the data and calculated adjusted HRs, RRs, or ORs with 95% confidence intervals (95% CI). When adjusted estimates were unavailable, we included unadjusted estimates and the number of events to calculate stroke incidence in the asthma and control groups. The  $I^2$  statistic was used to evaluate the heterogeneity of the included studies. To address the variability of each outcome of interest, an  $I^2 > 50\%$  was defined as significant heterogeneity (13), and we used the random-effects model. Data were analyzed with Stata version 14.0 (Stata Corp., College Station, TX) or Review Manager 5.3 software (2014; The Nordic Cochrane Center, The Cochrane Collaboration, Copenhagen, Denmark).

## **Additional Analyses**

We conducted subgroup analyses investigating the risk of stroke of people with asthma in different stroke types (including ischemic stroke and hemorrhagic stroke) and different populations including asthma status, smoking status, gender and age of asthma onset. We also conducted sensitivity analyses to test the robustness of results.

# RESULTS

Our searches identified 254 articles. After applying the inclusion and exclusion criteria, we included 18 observational studies (9, 14–30) (**Figure 1**). Among these, 2 studies (21, 22) were identified in the manual search and 16 studies (9, 14–20, 23–30) were identified in the electronic search.

Abbreviations: CI, confidential interval; ORs, odds ratios; RR, relative risk; HRs, hazard ratios; NOS, Newcastle-Ottawa Scale; PRISMA, Preferred Reporting Items for Systematic Reviews and Meta-Analyses; MOOSE, Meta-Analysis of Observational Studies in Epidemiology; PROSPERO, Prospective Register of Systematic Reviews; SE, standard error; IV, Inverse Variance method; df, degrees of freedom; a/f, adult female; a/m, adult male; c/f, child female; c/m, child male; c-s, current smoking; f-s, former smoking; n-s, never smoking.



## **Description of Studies**

Among 18 the observational studies included, 10 were crosssectional studies (21–30). Of these, 2 were cohort studies (21, 28) that did not have outcomes of interest, but reported crosssectional data on the association between asthma and stroke in the baseline characteristics of the population. The other 8 cross-sectional cohort studies (9, 14–20) included 2 retrospective studies (17, 19) and 6 prospective studies (9, 14–16, 18, 20).

We collected baseline patient characteristics from each study (**Table 1**). The combined populations of these studies yielded a total of 3,011,016 participants. Six studies were conducted in Asia, 6 were conducted in North America, 4 were conducted in Europe, and 2 were conducted in Oceania. The quality assessments with the NOS (**Supplementary Table 3**) showed that 4 studies were high quality, 10 were medium quality, and 4 were low quality. Six studies presented data about the risk of ischemic stroke in patients with asthma, and 3 studies presented data about the risk of hemorrhagic stroke in patients with asthma. Some studies examined the impact of asthma on stroke in different subgroups, based on sex, smoking status, asthma status, and age of asthma onset.

# Association Between Asthma and Stroke

We analyzed 18 studies and 26 subsets with a random-effects model. That analysis revealed that patients with asthma had a 34% higher risk of stroke than individuals without asthma (RR: 1.34, 95% CI: 1.21–1.47, p < 0.00001;  $I^2$ : 89%, p < 0.00001). Most of the subsets (22 of 26) showed an increased risk of stroke in patients with asthma, but the heterogeneity was pronounced. Moreover, the risk of stroke was significantly increased with asthma, in both the cohort studies (RR: 1.24, 95% CI: 1.08–1.42, p = 0.003) and the cross-sectional studies (RR: 1.55, 95% CI: 1.27–1.88, p < 0.00001), and no difference was found between analysis results of cohort studies and cross-sectional studies (p = 0.07 for between-group difference) (**Figure 2**).

We also measured the effects of asthma on ischemic and hemorrhagic stroke. Patients with asthma had 25% more risk of ischemic stroke compared to people without asthma, and this difference was significant (RR: 1.25, 95% CI: 1.06–1.47, p < 0.00001;  $I^2$ : 93%, p < 0.00001). In contrast, the probability of hemorrhagic stroke did not increase significantly in patients with asthma (RR: 1.08, 95% CI: 0.87–1.34, p = 0.49;  $I^2$ : 87%, p < 0.0001) (**Figure 3**).

TABLE 1 | Baseline characteristics of participants assessed in the studies included in the meta-analysis.

References					Total					Confounding factors adjusted for in the analyses	NOS score
	Population	Participant number	Study Type	Follow-up, mean or (range)	Age, range or (mean $\pm$ SD)	Gender (female, %)	Diagnosis criteria of asthma	Diagnosis criteria of stroke	Comorbidities, n (%)		
Onufrak et al. (15)	Community	14,567	Cohort study, prospective	12–14	45–64	56.9%	Self-reported	Doctor diagnosis	DM:10.9%, HTN:33.5%, CB:8.4%, emphysema:1.6%	NA	7
Chung et al. (17)	Community	72,587	Cohort study, retrospective	7.2	52.1 ± 17.6	54.3%	Electronic medical record	Electronic medical record	AF:0.5%, HTN:29.1%, HPL: 16.2%, HF:2.0%, COPD: 9.9%, DVT:0.1%, CHD:13.7%	Age, sex and comorbidities of AF, HTN, HPL, HF, alcoholism, obesity, COPD, DVT and CHD	7
Çolak et al. (18)	Community	94,079	Cohort study, prospective	<9.4	56.1	59.2%	Doctor diagnosis	Doctor diagnosis	Pneumonia or acute bronchitis:22.5%	Age, sex, BMI, leisure time physical activity, education, annual household income, alcohol, cumulative tobacco consumption, BP, TC, LDL-C, HDL-C, TG, use of cholesterol-lowering medication, and DM	7
Kim et al. (19)	Community	234,728	Cohort study, retrospective	<12	>20	63.7%	Electronic medical record	Electronic medical record	HTN:38.8%, DM:20%, IHD:6.8%, depression:10.4%, dyslipidemia:28.2%	Age, sex, income, region of residence, HTN, DM, HPL, IHD, depression histories	8
Cepelis et al. (16)	Community	57,104	Cohort study, prospective	17.2 ± 5.4	>20	52.9%	Self-reported	Electronic medical record	DM:2.2%, HTN:37.5%	Age, birth year cohort, sex, BMI, smoking status, alcohol use, education level, TC/HDL ratio, HTN, DM	8
Iribarren et al. (20)	Community	407,190	Cohort study, prospective	2.3–9.3	≥18	66.0%	Electronic medical record	Electronic medical record	HTN:7.2%, DM:5.6%, HPL:6.1%	DM, HTN, HPL, BMI, smoking status and history of any allergy	7
Schanen et al. (14)	Community	13,501	Cohort study, prospective	≥14	$54 \pm 5.9$	57.0%	Self-reported	Electronic medical record	DM:10.7%, HTN:23.5%	Age, sex, race/center, HDL-C, LDL-C, BP, HTN medication use smoking status, pack years, WHR, DM, and sport score	8
Tattersal et al. (9)	Community	6,792	Cohort study, prospective	9.1 ± 2.8	62.1 ± 10.2	52.9%	Self-reported	Electronic medical record	DM:12.6%	Age, race, sex, TC, HDL-C, BP, smoking, DM, anti-HTN and lipid-lowering medication use, BMI, family history of CVD, income	8
Wee et al. (29)	Community	162,570	Cross-sectional study		53.3 ± 8.4	65.7%	Self-reported	Electronic medical record	HTN:22.5%, DM:8.0%, HPL:13.4%, IHD:3.1%	Age, sex, income, BMI, smoking alcohol, HTN,DM,HPL, other allergic rhinitis histories, nutritional intake	, 7

(Continued)

Association Between Asthma and Stroke

References					Total					Confounding factors adjusted for in the analyses	NOS score
	Population	Participant number	Study Type	Follow-up, mean or (range)	Age, range or (mean ± SD)	Gender (female, %)	Diagnosis criteria of asthma	Diagnosis criteria of stroke	Comorbidities, <i>n</i> (%)	-	
Enright et al. (22)	Community	5,169	Cross-sectional study		72.8 ± 5.6	57.0%	Self-reported	Electronic medical record	NA	NA	5
Lee et al. (24)	Community	16,943	Cross-sectional study		49.5 ± 10.0	51.7%	Self-reported	Doctor diagnosis	DM:7.7%, MI:3.2%, CHD:5.6%	Age, BP, HDL-C, BMI, Hs-CRP, smoking, and DM	6
Adams et al. (30)	Community	7,443	Cross-sectional study		≥18	49.1%	Self-reported	Self-reported	NA	Age and sex	5
Appleton et al. (23)	Community	4,060	Cross-sectional study		≥18	NA	Doctor diagnosis	Self-reported	DM:13.0%, CVD:12.3%, Metabolic syndrome:45.7%	Age (>50 years), sex, smoking, MI	6
Bozek et al. (26)	Community	2,099	Cross-sectional study		67.9 ± 5.6	53.6%	Doctor diagnosis	Electronic medical record	HTN:44.5%, HPL:48.0%, CHD:23.6%, arrhythmias:2.6%, HF:18.6%, hyperuricemia:6.0%, dementia: 4.1%, depression: 17.5%, delirium:4.1%, anxiety:8.9%	NA	5
Park et al. (25)	) Community	4,445	Cross-sectional study		46–68	58.4%	Electronic medical record	Self-reported	Arthritis:28.6%, HTN:37.7%, Dyslipidemia:32.7%, DM:12.6%, Depression:16.6%, Obesity:11.9%	NA	6
Weatherburn et al. (27)	Community	1,424,378	Cross-sectional study		≥18	50.9%	Electronic medical record	Electronic medical record	COPD:3.7%, HF:1.3%, CHD:5.7%, DM:5.3%, HTN:16.5%, AF:15.7%	Age, sex, deprivation, smoking	6
Strand et al. (28)	Community	446,346	Cross-sectional study		40.0 ± 13.5	50.9%	Self-reported	Self-reported	DM:8.8%, CHD:3.3%, cancer:9.3%, arthritis:24.1%	NA	5
He et al. (21)	Community	37,015	Cross-sectional study		≥20	51.9%	Self-reported	Electronic medical record	DM:8.8%, CHD:3.3%, cancer:9.3%, arthritis: 24.1%	NA	6

AF, atrial fibrillation; BMI, body mass index; BP, blood pressure; CB, chronic bronchitis; CVD, cardiovascular disease; CHD, coronary heart disease; DM, diabetes mellitus; DVT, deep vein thrombosis; HDL, high-density lipoprotein; HDL-C, high-density lipoprotein cholesterol; HPL, hyperlipidemia; HTN, hypertension; HF, heart failure; LDL, low-density lipoprotein; LDL-C, low-density lipoprotein cholesterol; MI, myocardial infarction; NA, not available; TC, total cholesterol; TG, triglycerides; WHR, waist-hip ratio.

Study or Subgroup	log[Pick Patio] SI	Weight	Risk Ratio	Risk Ratio
1 1 1 cohort studies		. weight	1v, Kandoni, 3378 C	
Copolis 2019	0.0677 0.060	6.8%		Ļ
Cepells 2019	0.0077 0.0007	0.0% 7 7 2%	1.07 [0.95, 1.21]	-
	1 0096 0 2060	7.2%	3 00 [2 00 4 50]	
Colok, c-S 2015	0.2412 0.176	2 2 00/		+ <b>-</b> -
Çolak, 1-5 2015	0.2412 0.1700	3 3.8 / 0	1.27 [0.90, 1.00]	
çolak, non-sinoke 2015	0.3103 0.2102	7 7 50/	1.37 [0.90, 2.10]	
kim homorrhagia 2010	0.1623 0.0217	7.5%		-
kimi, hemorragic 2019		7.0%		
Construction of 2008	-0.0943 0.0200	0 7.4%		
Onullak, a/r 2008	0.0007 0.200		2.30 [1.40, 3.70]	
Onullak, a/iii 2006	-1.0490 0.0928			
Onuliak, c/l 2006	0.3033 0.3300	0 1.7%	1.47 [0.76, 2.64]	
	-0.4308 0.4118	3 1.2%	0.65 [0.29, 1.46]	
Schanen 2005	0.4055 0.1868	0 3.7%	1.50 [1.04, 2.16]	
Tattersal, active 2015	0.4947 0.42	2 1.2%	1.64 [0.72, 3.74]	
Tattersal, non-active 2015	0.0583 0.2988	50.2%	1.06 [0.59, 1.90]	▲
	01.2 400.04 15 44 (D	59.5%	1.24 [1.00, 1.42]	•
Heterogeneity: $Tau^2 = 0.04$ ;	$Chi^2 = 160.01$ , df = 14 (P	< 0.00001	); $1^2 = 91\%$	
1 1 2 cross-sectional stud	ies			
Adams 2006	0.0405 0.240	2.7%	2 56 [1 60 / 10]	
Appleton 2008	0.9403 0.240	2.7%	1 84 [1 11 3 05]	_ <b>_</b> _
Bozek 2016	0.6041 0.150	7 <u>15%</u>	2 00 [1 /0 2 60]	-
Epright 1996	0.0341 0.1307	-1.0%	1 52 [0 83 2 79]	
	0.3273 0.069	6.6%	1 30 [1 21 1 50]	-
Lee adult-onset 2012	0.3273 0.0030	7 1.2%	2 09 [0 94 4 65]	
Lee, addit-onset 2012	0.7372 0.4077	5 0.5%	2.09 [0.94, 4.03]	
Dark 2013	0 3538 0 318	1 0.5%	1.00 [0.20, 3.37]	
Strand at al. 2018	0.5550 0.510	6.1%	1.42 [0.70, 2.00]	-
Weatherburn 2017	0.0900 0.090-	75%	1.02 [1.02, 2.17]	
	0.0955 0.0108	5 5 20/		
Subtotal (95% CI)	0.137 0.1220	40.7%	1 55 [1 27 1 88]	•
Hotorogonoity: $Tau^2 = 0.07$ :	$Chi^2 = 60.80 df = 10 / D$	0 000011	12 - 96%	•
Test for overall effect: $Z = 4$ .	.39 (P < 0.0001)	s 0.0000 r <i>)</i> ,	1 00 %	
Total (95% CI)		100.0%	1.34 [1.21, 1.47]	
Heterogeneity: Tau <sup>2</sup> = 0.03;	Chi <sup>2</sup> = 233.32, df = 25 (P	< 0.00001)	); I² = 89%	
Test for overall effect: Z = 5.	.82 (P < 0.00001)			0.01 0.1 1 10 100
Test for subaroup difference	es: Chi² = 3.38. df = 1 (P =	= 0.07). I <sup>2</sup> =	70.4%	
GURE 2   Forest plot shows asso	ciation between asthma and	risk of stroke	e. SE, standard error; IV, Ir	nverse Variance method; df, degrees of freedom; Cl,

# Association Between Asthma and Stroke in Different Populations

Next, we examined the risk of stroke in different populations. The risk of stroke was significantly increased in both men (RR: 1.20, 95% CI: 1.10–1.32, p < 0.0001;  $I^2$ : 24%, p = 0.22) and women (RR: 1.29, 95% CI: 1.12–1.48, p = 0.0005;  $I^2$ : 61%, p = 0.007) with asthma, compared to individuals without asthma (**Figure 4**). However, no significant difference was found between the sexes (p = 0.07 for between-group differences).

We also analyzed whether smoking status influenced the association between asthma and stroke risk. The subgroups of smoking included ever smokers (those that had smoked in the past or were smoking currently), and non-smokers (those that had never smoked). The reference subgroups were individuals with the same smoking status, but without asthma. We found that, among patients that did not have history of smoking, those with asthma did not have an elevated risk of stroke, compared to those without asthma (RR: 1.18, 95% CI: 1.03–1.37, p = 0.02;  $I^2$ : 0%, p = 0.39). Conversely, we found that, among patients with a smoking history, those with asthma had an elevated risk of stroke, compared to those without asthma (RR: 0.99, 95% CI: 0.81–1.22, p = 0.95;  $I^2$ : 42%, p = 0.18; **Figure 5**).

Next, we compared patients with active asthma to patients with inactive asthma. Active asthma was defined as either a negative response to the question, "Do you still have asthma?" (14, 21), or evidence that the patient had not recently used asthma

			Risk Ratio	R	isk Ratio	
Study or Subgroup	log[Risk Ratio]	SE Weig	ht IV, Random, 95%	CI IV, Ra	<u>ndom, 95% Cl</u>	
1.5.1 ischemic stroke						
Cepelis 2019	0.0677 0.	.0607 9.8	3% 1.07 [0.95, 1.21	]	T	
Chung, ischemic 2014	0.3221 0.	0424 10.3	3% 1.38 [1.27, 1.50	)]	-	
Çolak, c-s 2015	1.0986 0.	2069 5.1	3.00 [2.00, 4.50	)]		
Çolak, f-s 2015	0.2412 0.	1768 5.9	9% 1.27 [0.90, 1.80	)]	<b>†-</b>	
Çolak, non-smoke 2015	0.3183 0.	2162 4.8	3% 1.37 [0.90, 2.10	)]	<b>†</b> •-	
Iribarren, ischemic 2012	0.1222 0.	0375 10.4	1.13 [1.05, 1.22	2]	•	
kim,ischemic 2019	-0.0943 0.	0288 10.5	0.91 [0.86, 0.96	5]	•	
Wee 2021	0.157 0.	1226 7.7	7% 1.17 [0.92, 1.49	9]	<b>T</b>	
Subtotal (95% CI)		64.4	1.25 [1.06, 1.47	]	•	
Heterogeneity: Tau <sup>2</sup> = 0.04;	Chi <sup>2</sup> = 97.18, df = 7 (	P < 0.00001	); I² = 93%			
Test for overall effect: Z = 2.	.63 (P = 0.008)					
1.5.2 hemorrhagic stroke						
Chung, hemorrhagic 2014	0.2927 0.	1054 8.3	1.34 [1.09, 1.65	5]	-	
Iribarren, ICH 2012	0.1655 0.	0694 9.5	5% 1.18 [1.03, 1.35	5]	-	
Iribarren, SAH 2012	0.0296 0.	1226 7.7	7% 1.03 [0.81, 1.31	]	+	
kim, hemorrhagic 2019	-0.1508 0.	0498 10.1	0.86 [0.78, 0.95	5]		
Subtotal (95% CI)		35.0	5% 1.08 <mark>(</mark> 0.87, 1.34	]	•	
Heterogeneity: Tau <sup>2</sup> = 0.04;	Chi <sup>2</sup> = 22.62, df = 3 (	P < 0.0001)	l² = 87%			
Test for overall effect: Z = 0.	.70 (P = 0.49)					
Total (95% CI)		100.0	0% 1.18 [1.04, 1.34	]	•	
Heterogeneity: $Tau^2 = 0.04$ ;	Chi <sup>2</sup> = 123.15, df = 1 <sup>4</sup>	1 (P < 0.000	01); l <sup>2</sup> = 91%			
Test for overall effect: $Z = 2$ .	.61 (P = 0.009)	,		0.01 0.1	1 10	100

medication (9, 16). The risk of stroke was elevated in patients with active asthma (RR: 1.48, 95% CI: 1.12–1.95, p = 0.006;  $I^2$ : 72%, p = 0.01), but not in patients with inactive asthma (RR: 0.95, 95% CI: 0.80–1.13, p = 0.58;  $I^2$ : 10%, p = 0.34) (**Figure 6**). Thus, asthma activity had a significant effect on the association between asthma and stroke (p = 0.008 for the between-group difference).

We also analyzed the age of asthma onset and patient sex. Child-onset and adult-onset asthma were defined by the age of the first asthma onset. In two studies (15, 24), the cut-off ages were 18 and 21 years. The results showed that only women with adult-onset asthma had an increased risk of stroke, compared to individuals without asthma (RR: 2.30, 95% CI: 1.51–3.52, p = 0.001;  $I^2$ : 0%, p = 0.81) (Figure 7).

### **Sensitivity Analyses**

We performed sensitivity analyses to test the robustness of the main outcomes (**Supplementary Figures 1–5**). By omitting one study at a time and re-computing the pooled effect estimates, we did not find any significant difference in the results. We also analyzed the data with studies which did not adjust for blood lipid levels (or hyperlipidemia), blood pressure levels (or hypertension), or diabetes mellitus were omitted, and the result was robust (**Supplementary Figure 6**). Two studies with only an association between asthma and stroke but not have the study outcomes and 4 low quailty studies might reduce the quality of the data. We analyzed the data with these studies omitted and the result was robust (**Supplementary Figure 7**).

# **Publication Bias**

The publication bias was evaluated with a funnel plot. The funnel plot was visually symmetrical overall (**Supplementary Figure 8**).

# DISCUSSION

This study assessed the effects of asthma on stroke by including previous studies comprehensively, particularly those with data for different populations. Our results showed that patients with asthma had a 34% higher risk of stroke than those without asthma. Furthermore, active asthma significantly increased the risk of stroke compared to inactive asthma (RR: 1.48 vs. RR: 0.95, p = 0.008). These results were consistent with previous studies, which showed that asthma, particularly active asthma, significantly increased the risk of stroke (11).

The chronic inflammatory state of asthma accelerates the process of atherosclerosis, which can lead to the development of stroke (9). Asthma and stroke share many common risk factors, including advanced age, smoking, obesity, air pollution, and stress. Thus, the association between asthma and stroke is, to some extent, affected by confounding factors (18, 31). Previous studies have pointed out that asthma was an independent risk factor for stroke. Asthma induced endothelial damage, accelerated atherosclerosis progression, and even caused thrombosis, due to decreased lung function and hypoxemia (4, 29). Previous studies have shown that elevated eosinophils (32),

Study or Subgroup log[Ris   1.2.1 male Cepelis, male 2019   Chung, male 2014 Chung, male 2014   Enright, male 1996 Iribarren, male 2012   Lee, a/m 2012 Lee, a/m 2012   Lee, c/m 2012 Chufrak, a/m 2008   Onufrak, c/m 2008 Wee, male(above53y) 2021   Wee, male(below53y) 2021 Contract	0.1222 0.2852 0.1283 0.1484 0.5068 0.2546 -1.0498 -0.4308	SE 0.0832 0.0525 0.4534 0.0412 0.6225 0.8372 0.6929	Weight 10.6% 14.8% 0.7% 16.4% 0.4%	IV. Random, 95% CI 1.13 [0.96, 1.33] 1.33 [1.20, 1.47] 1.14 [0.47, 2.76] 1.16 [1.07, 1.26] 1.66 [0.49, 5.62]	IV. Random, 95% Cl
I.2.1 male Cepelis, male 2019 Chung, male 2014 Enright, male 1996 ribarren, male 2012 Lee, a/m 2012 Lee, c/m 2012 Dnufrak, a/m 2008 Dnufrak, c/m 2008 Nee, male(above53y) 2021 Nee, male(below53y) 2021	0.1222 0.2852 0.1283 0.1484 0.5068 0.2546 -1.0498 -0.4308	0.0832 0.0525 0.4534 0.0412 0.6225 0.8372 0.6929	10.6% 14.8% 0.7% 16.4% 0.4%	1.13 [0.96, 1.33] 1.33 [1.20, 1.47] 1.14 [0.47, 2.76] 1.16 [1.07, 1.26] 1.66 [0.49, 5.62]	-
Cepelis, male 2019 Chung, male 2014 Enright, male 1996 ribarren, male 2012 .ee, a/m 2012 .ee, c/m 2012 Dnufrak, a/m 2008 Dnufrak, c/m 2008 Vee, male(above53y) 2021 Vee, male(below53y) 2021	0.1222 0.2852 0.1283 0.1484 0.5068 0.2546 -1.0498 -0.4308	0.0832 0.0525 0.4534 0.0412 0.6225 0.8372 0.6929	10.6% 14.8% 0.7% 16.4% 0.4%	1.13 [0.96, 1.33] 1.33 [1.20, 1.47] 1.14 [0.47, 2.76] 1.16 [1.07, 1.26] 1.66 [0.49, 5.62]	-
Chung, male 2014 Enright, male 1996 ribarren, male 2012 .ee, a/m 2012 .ee, c/m 2012 Dnufrak, a/m 2008 Dnufrak, c/m 2008 Vee, male(above53y) 2021 Vee, male(below53y) 2021	0.2852 0.1283 0.1484 0.5068 0.2546 -1.0498 -0.4308	0.0525 0.4534 0.0412 0.6225 0.8372 0.6929	14.8% 0.7% 16.4% 0.4%	1.33 [1.20, 1.47] 1.14 [0.47, 2.76] 1.16 [1.07, 1.26] 1.66 [0.49, 5.62]	•
Enright, male 1996 ribarren, male 2012 .ee, a/m 2012 .ee, c/m 2012 Dnufrak, a/m 2008 Dnufrak, c/m 2008 Vee, male(above53y) 2021 Vee, male(below53y) 2021	0.1283 0.1484 0.5068 0.2546 -1.0498 -0.4308	0.4534 0.0412 0.6225 0.8372	0.7% 16.4% 0.4%	1.14 [0.47, 2.76] 1.16 [1.07, 1.26] 1.66 [0.49, 5.62]	•
ribarren, male 2012 .ee, a/m 2012 .ee, c/m 2012 Dnufrak, a/m 2008 Dnufrak, c/m 2008 Vee, male(above53y) 2021 Vee, male(below53y) 2021	0.1484 0.5068 0.2546 -1.0498 -0.4308	0.0412 0.6225 0.8372	16.4% 0.4%	1.16 [1.07, 1.26]	•
ee, a/m 2012 ee, c/m 2012 Dnufrak, a/m 2008 Dnufrak, c/m 2008 Vee, male(above53y) 2021 Vee, male(below53y) 2021	0.5068 0.2546 -1.0498 -0.4308	0.6225	0.4%	1 66 10 40 5 621	
Lee, c/m 2012 Dnufrak, a/m 2008 Dnufrak, c/m 2008 Wee, male(above53y) 2021 Wee, male(below53y) 2021	0.2546 -1.0498 -0.4308	0.8372	0.00/	1.00 [0.49, 0.02]	
Dnufrak, a/m 2008 Dnufrak, c/m 2008 Vee, male(above53y) 2021 Vee, male(below53y) 2021	-1.0498 -0.4308	0 6020	0.2%	1.29 [0.25, 6.66]	
Dnufrak, c/m 2008 Vee, male(above53y) 2021 Vee, male(below53y) 2021	-0.4308	0.0323	0.3%	0.35 [0.09, 1.36]	
Vee, male(above53y) 2021 Vee, male(below53y) 2021		0.4118	0.9%	0.65 [0.29, 1.46]	
Vee, male(below53y) 2021	0.1989	0.1844	3.8%	1.22 [0.85, 1.75]	+
	0.6931	0.4739	0.7%	2.00 [0.79, 5.06]	
Subtotal (95% CI)			48.8%	1.20 [1.10, 1.32]	•
Heterogeneity: Tau <sup>2</sup> = 0.00; Chi <sup>2</sup> = 11.85	, df = 9 (F	P = 0.22)	; l² = 24%		
Test for overall effect: Z = 3.97 (P < 0.00)	01)				
.2.2 female	0	0 0951	9.3%	1 00 [0 83 1 20]	+
Chung fomale 2014	0 3507	0.0951	1/ 10/	1 42 [1 27 1 50]	
Enright female 1996	0.3307	0.007	0.8%	2 11 [0 01 / 80]	
ribarren female 2012	0.1400	0.4203	17.0%	1 22 [1 15 1 29]	-
$a_{\text{po}} = 2/f 2012$	0.1303	0.0301	0.6%	2 06 [0 75 5 66]	
ee, a/12012	0.7227	1 0231	0.0%	0.52 [0.07, 3.86]	
)nufrak a/f 2008	0.8587	0 2381	2.4%	2 36 [1 48 3 76]	
Dufrak, c/f 2008	0.3853	0.2366	1.3%	1 47 [0 76 2 84]	
Vee female(above53v) 2021	0.0000	0.0000	3.8%	1 03 [0 72 1 47]	+
Vec, female(below53y) $2021$	0.0200	0.4586	0.7%	1 13 [0 46 2 78]	— <u> </u>
Subtotal (95% CI)	0.1222	0.4000	51.2%	1.29 [1.12, 1.48]	♦
deterogeneity: Tau2 = 0.02: Chi2 = 22.85	df = 9/F	P = 0.007	$1) \cdot l^2 = 61\%$		
Test for overall effect: $7 = 3.48$ (P = 0.00)	, a 0 (i 05)	0.007	,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,		
-0.000	00)				
otal (95% CI)			100.0%	1.23 [1.14, 1.33]	•
leterogeneity: $Tau^2 = 0.01$ ; Chi <sup>2</sup> = 35.50	, df = 19	(P = 0.01	); l <sup>2</sup> = 46%		
est for overall effect: Z = 5.29 (P < 0.00)	001)			0.01	0.1 1 10 100

FIGURE 4 | Forest plot shows association between asthma and the risk of stroke in male or female. SE, standard error; IV, Inverse Variance method; df, degrees of freedom; a/f, adult female; a/m, adult male; c/f, child female; c/m, child male.

Study or Subgroup	log[Risk Ratio]	SF	Weight	Risk Ratio IV. Fixed, 95% Cl		IV	Risk Ratio		
1.4.1 smoking			mergine					//	
Cepelis, smoke 2019	0.157	0.075	64.8%	1.17 [1.01, 1.36]			-		
Enright, smoke 1996	0.4973	0.389	2.4%	1.64 [0.77, 3.52]					
Subtotal (95% CI)			67.2%	1.18 [1.03, 1.37]			•		
Heterogeneity: Chi <sup>2</sup> = 0.74, df	i = 1 (P = 0.39); l <sup>2</sup>	= 0%							
Test for overall effect: Z = 2.3	0 (P = 0.02)								
1.4.2 non-smoking									
Cepelis, non-smoke 2019	-0.1278	0.1241	23.7%	0.88 [0.69, 1.12]			-		
Çolak, non-smoke 2015	0.3183	0.2162	7.8%	1.37 [0.90, 2.10]					
Enright, non-smoke 1996	0.2315	0.5126	1.4%	1.26 [0.46, 3.44]			_ <del></del>		
Subtotal (95% CI)			32.8%	0.99 [0.81, 1.22]			•		
Heterogeneity: Chi <sup>2</sup> = 3.43, df	= 2 (P = 0.18); I <sup>2</sup>	= 42%							
Test for overall effect: Z = 0.0	6 (P = 0.95)								
Total (95% CI)			100.0%	1.12 [0.99, 1.26]			•		
Heterogeneity: Chi <sup>2</sup> = 6.04, df	= 4 (P = 0.20); I <sup>2</sup>	= 34%						10	4.00
Test for overall effect: Z = 1.8	5 (P = 0.06)				0.01	0.1	Ĩ	10	100
Test for subgroup differences	$Chi^2 = 1.87 df =$	1(P = 0)	$(17)  ^2 = 4$	46.6%					

FIGURE 5 | Forest plot shows association between asthma and the risk of stroke in smoking or non-smoking people. SE, standard error; IV, Inverse Variance method; df, degrees of freedom.

Study or Subaroup	Iog[Pick Patio]	SE	Weight	IV Pandom 95% CI	RISK Ratio
1 4 1 active asthma		52	weight		
	0.457	0.0050	40.00/	4 47 10 07 4 441	-
Cepells, active 2019	0.157	0.0956	10.0%	1.17 [0.97, 1.41]	
He, active 2021	0.5582	0.0773	17.2%	1.75 [1.50, 2.03]	
Schanen, active 2005	0.4383	0.2498	10.5%	1.55 [0.95, 2.53]	-
Tattersal, active 2015	0.4947	0.42	5.9%	1.64 [0.72, 3.74]	
Subtotal (95% CI)			50.3%	1.48 [1.12, 1.95]	$\bullet$
Heterogeneity: Tau <sup>2</sup> = 0.	05; Chi <sup>2</sup> = 10.72, df	= 3 (P =	0.01); l <sup>2</sup> =	72%	
Test for overall effect: Z	= 2.75 (P = 0.006)				
1.4.2 inactive asthma					
Cepelis, inactive 2019	-0.0513	0.1139	16.0%	0.95 [0.76, 1.19]	+
He, inactive 2021	-0.1785	0.1336	15.2%	0.84 [0.64, 1.09]	
Schanen, inactive 2005	0.3646	0.275	9.6%	1.44 [0.84, 2.47]	<b>+-</b>
Tattersal,inactive 2015	0.0583	0.2989	8.9%	1.06 [0.59, 1.90]	
Subtotal (95% CI)			49.7%	0.95 [0.80, 1.13]	◆
Heterogeneity: Tau <sup>2</sup> = 0.	00; Chi <sup>2</sup> = 3.33, df =	= 3 (P = 0	).34); l <sup>2</sup> = 1	0%	
Test for overall effect: Z	= 0.55 (P = 0.58)		,.		
Total (95% CI)			100.0%	1.22 [0.96, 1.56]	◆
	$08 \cdot Chi^2 = 35.61 df$	= 7 (P <	0.00001)	$l^2 = 80\%$	
Heterogeneity: I au <sup>2</sup> = 0.1	00, 011 - 00.01, 01	- / (1 -	0.00001),	1 0070	0.01 0.1 1 10 100

FIGURE 6 | Forest plot shows association between different asthma status (including active asthma and inactive asthma) and the risk of stroke. SE, standard error; IV, Inverse Variance method; df, degrees of freedom.



Variance method; df, degrees of freedom; a/f, adult female; a/m, adult male; c/f, child female; c/m, child male.

C-reactive protein (33), eosinophil cationic protein (34), and eotaxin (35) were involved in the development of atherosclerosis in patients with asthma. These features might explain why active asthma increases the risk of stroke: in active asthma, inflammation is severe and hypoxemia is prolonged, and these factors accelerate the atherosclerotic process.

Previous studies have suggested that asthma caused similar increases in the risks of ischemic and hemorrhagic stroke. In contrast, the present study showed that asthma mainly increased the risk of ischemic stroke and had less effect on the risk of hemorrhagic stroke. Our findings were supported by the association between asthma and atherosclerosis. Indeed, atherosclerosis directly drives thrombosis, which leads to ischemic stroke, and it is much less related to hemorrhagic stroke. In contrast, the main risk factors for hemorrhagic stroke are trauma and congenital vascular developmental malformations, which are more weakly associated with asthma.

The greatest strength of this study was that it included the largest sample size of any study to date that aimed to analyze the relationship between asthma and stroke. Moreover, we characterized the effect of smoking status on this association with a sufficiently sized subgroup analysis.

#### Limitations

However, this study also had some limitations. First, unfortunately, we could not obtain sufficient data on patient asthma treatments to analyze their effects on stroke risk. Previous studies have shown that asthma treatment medications, like  $\beta$  receptor-agonists and glucocorticoids, could influence stroke outcomes (36–39). Moreover, we only included observational studies; therefore, we could not infer any direct causal relationships. Additionally, observational studies are susceptible to confounding factors that may bias the results. Finally, the heterogeneity of the included studies was not negligible; therefore, our results should be interpreted with caution.

#### Conclusions

In conclusion, this meta-analysis provided evidence to support the notion that asthma is an important risk factor for stroke. This information is important for the development of strategies for preventing and treating asthma and stroke. In the future, welldesigned, large, multicenter cohort studies should be conducted with a particular focus on a quantitative assessment of the effects of asthma on patients during stroke treatment.

## DATA AVAILABILITY STATEMENT

The original contributions presented in the study are included in the article/**Supplementary Material**,

### REFERENCES

 Vos T, Flaxman AD, Naghavi M, Lozano R, Michaud C, Ezzati M, et al. Years lived with disability (YLDs) for 1160 sequelae of 289 diseases and injuries 1990-2010: a systematic analysis for the Global Burden of Disease further inquiries can be directed to the corresponding author/s.

## **AUTHOR CONTRIBUTIONS**

Z-FL: analysis of data, interpretation results, drafting, and editing the article. Z-HF, Z-YA, S-CH, M-DH, and W-XZ: design of study, solution of problem, and reviewing the article. S-CH and M-DH: extraction of data and assessment of articles quality. All authors contributed to the article and approved this version of article.

### SUPPLEMENTARY MATERIAL

The Supplementary Material for this article can be found online at: https://www.frontiersin.org/articles/10.3389/fneur. 2022.900438/full#supplementary-material

Supplementary Figure 1 | Sensitivity analysis of association between asthma and the risk of stroke. Cl, confidential interval; a/f, adult female; a/m, adult male; c/f, child female; c/m, child male; c-s, current smoking; f-s, former smoking; n-s, never smoking.

**Supplementary Figure 2** Sensitivity analysis of association between asthma and the risk of stroke (only cohort studies included). CI, confidential interval; a/f, adult female; a/m, adult male; c/f, child female; c/m, child male; c-s, current smoking; f-s, former smoking; n-s, never smoking.

Supplementary Figure 3 | Sensitivity analysis of association between asthma and the risk of stroke (only cross-sectional studies included). Cl, confidential interval.

Supplementary Figure 4 | Sensitivity analysis of association between asthma and the risk of stroke in male. CI, confidential interval; a/m, adult male; c/m, child male.

Supplementary Figure 5 | Sensitivity analysis of association between asthma and the risk of stroke in female. CI, confidential interval; a/f, adult female; c/f, child female.

Supplementary Figure 6 | Association between asthma and the risk of stroke (studies which did not adjust blood lipid, blood pressure, or diabetes mellitus were omitted). SE, standard error; IV, Inverse Variance method; df, degrees of freedom; CI, confidential interval; a/f, adult female; a/m, adult male; c/f, child female; c/m, child male; c-s, current smoking; f-s, former smoking; n-s, never smoking.

**Supplementary Figure 7** Association between asthma and the risk of stroke (Two studies with only an association between asthma and stroke but not have the study outcomes and 4 low quaity studies were omitted). SE, standard error; IV, Inverse Variance method; df, degrees of freedom; CI, confidential interval; a/f, adult female; a/m, adult male; c/f, child female; c/m, child male; c-s, current smoking; f-s, former smoking; n-s, never smoking.

**Supplementary Figure 8** | Funnel plot depicting publication bias for the association between asthma and the risk of stroke. SE, standard error; RR, risk ratio.

Supplementary Table 1 | PRISMA 2009 checklist.

Supplementary Table 2 | Search strategies.

Supplementary Table 3 | Newcastle-Ottawa scale for assessing the quality of included studies.

Study 2010. Lancet. (2012) 380:2163-96. doi: 10.1016/S0140-6736(12)6 1729-2

 Holgate ST, Wenzel S, Postma DS, Weiss ST, Renz H, Sly PD. Asthma. Nat Rev Dis Primers. (2015) 1:15025. doi: 10.1038/nrdp. 2015.25

- Bazan-Socha S, Mastalerz L, Cybulska A, Zareba L, Kremers R, Zabczyk M, et al. Prothrombotic state in asthma is related to increased levels of inflammatory cytokines, IL-6 and TNF alpha, in peripheral blood. *Inflammation*. (2017) 40:1225–35. doi: 10.1007/s10753-017-0565-x
- Tuleta I, Skowasch D, Aurich F, Eckstein N, Schueler R, Pizarro C, et al. Asthma is associated with atherosclerotic artery changes. *PLoS ONE*. (2017) 12:e0186820. doi: 10.1371/journal.pone.0186820
- 5. Hankey GJ. Stroke. *Lancet.* (2017) 389:641–54. doi: 10.1016/S0140-6736 (16)30962-X
- Cepelis A, Brumpton BM, Laugsand LE, Dalen H, Langhammer A, Janszky I, et al. Asthma, asthma control and risk of acute myocardial infarction: HUNT study. *Eur J Epidemiol.* (2019) 34:967–77. doi: 10.1007/s10654-019-00562-x
- O'Donnell MJ, Chin SL, Rangarajan S, Xavier D, Liu LS, Zhang HY, et al. Global and regional effects of potentially modifiable risk factors associated with acute stroke in 32 countries (INTERSTROKE): a case-control study. *Lancet*. (2016) 388:761–75. doi: 10.1016/S0140-6736(16)30506-2
- Lindsay MP, Norrving B, Sacco RL, Brainin M, Hacke W, Martins S, et al. World stroke organization (WSO): global stroke fact sheet 2019. *Int J Stroke*. (2019) 14:806–17. doi: 10.1177/1747493019881353
- Tattersall MC, Guo M, Korcarz CE, Gepner AD, Kaufman JD, Liu KJ, et al. Asthma predicts cardiovascular disease events: the multi-ethnic study of atherosclerosis. *Arterioscler Thromb Vasc Biol.* (2015) 35:1520–5. doi: 10.1161/ATVBAHA.115.305452
- Portegies ML, Lahousse L, Joos GF, Hofman A, Koudstaal PJ, Stricker BH, et al. Chronic obstructive pulmonary disease and the risk of stroke. The Rotterdam Study. *Am J Respir Crit Care Med.* (2016) 193:251–8. doi: 10.1164/rccm.201505-0962OC
- Wen LY, Ni H, Li KS, Yang HH, Cheng J, Wang X, et al. Asthma and risk of stroke: a systematic review and meta-analysis. *J Stroke Cerebrovasc Dis.* (2016) 25:497–503. doi: 10.1016/j.jstrokecerebrovasdis.2015.11.030
- Hutton B, Salanti G, Caldwell DM, Chaimani A, Schmid CH, Cameron C, et al. The PRISMA extension statement for reporting of systematic reviews incorporating network meta-analyses of health care interventions: checklist and explanations. *Ann Intern Med.* (2015) 162:777–84. doi: 10.7326/M14-2385
- Higgins JP, Thompson SG. Quantifying heterogeneity in a meta-analysis. Stat Med. (2002) 21:1539–58. doi: 10.1002/sim.1186
- Schanen JG, Iribarren C, Shahar E, Punjabi NM, Rich SS, Sorlie PD, et al. Asthma and incident cardiovascular disease: the atherosclerosis risk in communities study. *Thorax*. (2005) 60:633–8. doi: 10.1136/thx.2004.026484
- Onufrak SJ, Abramson JL, Austin HD, Holguin F, McClellan WM, Vaccarino LV. Relation of adult-onset asthma to coronary heart disease and stroke. *Am J Cardiol.* (2008) 101:1247–52. doi: 10.1016/j.amjcard.2007.12.024
- Cepelis A, Brumpton BM, Laugsand LE, Langhammer A, Janszky I, Strand LB. Asthma, asthma control and risk of ischemic stroke: the HUNT study. *Respir Med X*. (2020) 2:13. doi: 10.1016/j.yrmex.2019.100013
- Chung WS, Lin CL, Chen YF, Ho FM, Hsu WH, Kao CH. Increased stroke risk among adult asthmatic patients. *Eur J Clin Invest.* (2014) 44:1025–33. doi: 10.1111/eci.12336
- Çolak Y, Afzal S, Nordestgaard BG, Lange P. Characteristics and prognosis of never-smokers and smokers with asthma in the copenhagen general population study: a prospective cohort study. *Am J Respir Crit Care Med.* (2015) 192:172–81. doi: 10.1164/rccm.201502-0302OC
- Kim SY, Lim H, Lim JS, Choi HG. Analysis of the relationship between adult asthma and stroke: a longitudinal follow-up study using the Korean National sample cohort. *BioMed Res Int.* (2019) 2019:230. doi: 10.1155/2019/8919230
- Iribarren C, Tolstykh IV, Miller MK, Sobel E, Eisner MD. Adult asthma and risk of coronary heart disease, cerebrovascular disease, and heart failure: a prospective study of 2 matched cohorts. *Am J Epidemiol.* (2012) 176:1014–24. doi: 10.1093/aje/kws181
- He XM, Cheng GS, He L, Liao B, Du YJ, Xie XG, et al. Adults with current asthma but not former asthma have higher all-cause and cardiovascular mortality: a population-based prospective cohort study. *Sci Rep-Uk.* (2021) 11:1329. doi: 10.1038/s41598-020-79264-4
- Enright PL, Ward BJ, Tracy RP, Lasser EC. Asthma and its association with cardiovascular disease in the elderly. The cardiovascular health study research group. J Asthma. (1996) 33:45–53. doi: 10.3109/02770909609077762
- Appleton SL, Ruffin RE, Wilson DH, Taylor AW, Adams RJ. Asthma is associated with cardiovascular disease in a representative population sample. *Obesity Res Clin Pract.* (2008) 2:91–9. doi: 10.1016/j.orcp.2008.04.005

- Lee HM, Truong ST, Wong ND. Association of adult-onset asthma with specific cardiovascular conditions. *Respir Med.* (2012) 106:948–53. doi: 10.1016/j.rmed.2012.02.017
- 25. Park J, Kim TB, Joo H, Lee JS, Lee SD, Oh YM. Diseases concomitant with asthma in middle-aged and elderly subjects in Korea: a population-based study. *Allergy Asthma Immunol Res.* (2013) 5:16–25. doi: 10.4168/aair.2013.5.1.16
- Bozek A, Rogala B, Bednarski P. Asthma, COPD and comorbidities in elderly people. J Asthma. (2016) 53:943–7. doi: 10.3109/02770903.2016.1170139
- Weatherburn CJ, Guthrie B, Mercer SW, Morales DR. Comorbidities in adults with asthma: population-based cross-sectional analysis of 14 million adults in Scotland. *Clin Exp Allergy*. (2017) 47:1246–52. doi: 10.1111/cea.12971
- Strand LB, Tsai MK, Wen CP, Chang SS, Brumpton BM. Is having asthma associated with an increased risk of dying from cardiovascular disease? A prospective cohort study of 446 346 Taiwanese adults. *BMJ Open.* (2018) 8:e019992. doi: 10.1136/bmjopen-2017-019992
- 29. Wee JH, Park MW, Min C, Byun SH, Park B, Choi HG. Association between asthma and cardiovascular disease. *Eur J Clin Invest.* (2021) 51. doi: 10.1111/eci.13396
- Adams RJ, Wilson DH, Taylor AW, Daly A, D'Espaignet ET, Dal Grande E, et al. Coexistent chronic conditions and asthma quality of life: a populationbased study. *Chest.* (2006) 129:285–91. doi: 10.1378/chest.129.2.285
- Katan M, Luft A. Global burden of stroke. Semin Neurol. (2018) 38:208–11. doi: 10.1055/s-0038-1649503
- Fulkerson PC, Rothenberg ME. Targeting eosinophils in allergy, inflammation and beyond. Nat Rev Drug Discov. (2013) 12:117–29. doi: 10.1038/nrd3838
- Tsimikas S, Willerson JT, Ridker PM. C-reactive protein and other emerging blood biomarkers to optimize risk stratification of vulnerable patients. *J Am Coll Cardiol*. (2006) 47(Suppl. 8):C19–31. doi: 10.1016/j.jacc.2005.10.066
- Niccoli G, Ferrante G, Cosentino N, Conte M, Belloni F, Marino M, et al. Eosinophil cationic protein: a new biomarker of coronary atherosclerosis. *Atherosclerosis.* (2010) 211:606–11. doi: 10.1016/j.atherosclerosis.2010.02.038
- Emanuele E, Falcone C, D'Angelo A, Minoretti P, Buzzi MP, Bertona M, et al. Association of plasma eotaxin levels with the presence and extent of angiographic coronary artery disease. *Atherosclerosis.* (2006) 186:140–5. doi: 10.1016/j.atherosclerosis.2005.07.002
- Sneeboer MMS, Majoor CJ, de Kievit A, Meijers JCM, van der Poll T, Kamphuisen PW, et al. Prothrombotic state in patients with severe and prednisolone-dependent asthma. J Allergy Clin Immunol. (2016) 137:1727–32. doi: 10.1016/j.jaci.2015.10.038
- Podgórski M, Kupczyk M, Grzelak P, Bocheńska-Marciniak M, Polguj M, Kuna P, et al. Inhaled corticosteroids in asthma: promoting or protecting against atherosclerosis? *Med Sci Monit.* (2017) 23:5337–44. doi: 10.12659/MSM.904469
- Camargo CA, Barr RG, Chen R, Speizer FE. Prospective study of inhaled corticosteroid use, cardiovascular mortality, and all-cause mortality in asthmatic women. *Chest.* (2008) 134:546–51. doi: 10.1378/chest.07-3126
- Cazzola M, Rogliani P, Calzetta L, Matera MG. Bronchodilators in subjects with asthma-related comorbidities. *Respir Med.* (2019) 151:43–8. doi: 10.1016/j.rmed.2019.04.001

**Conflict of Interest:** The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

**Publisher's Note:** All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.

Copyright © 2022 Fang, Li, An, Huang, Hao and Zhang. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.